• LAST PRICE
    0.7800
  • TODAY'S CHANGE (%)
    Trending Down-0.0100 (-1.2658%)
  • Bid / Lots
    0.7503/ 14
  • Ask / Lots
    0.8100/ 1
  • Open / Previous Close
    0.7900 / 0.7900
  • Day Range
    Low 0.7111
    High 0.8600
  • 52 Week Range
    Low 0.4250
    High 1.6100
  • Volume
    96,785
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.79
TimeVolumeTLPH
09:36 ET27210.78
09:43 ET33070.79
09:54 ET2500.790201
10:26 ET1000.86
10:32 ET8000.82
10:33 ET1000.85
10:37 ET1000.82
10:39 ET1500.8
10:42 ET21000.81
11:09 ET16700.8
11:11 ET16000.82
11:33 ET1420.814899
11:44 ET1000.79
11:47 ET22890.79
11:49 ET1000.771
12:18 ET31000.78
12:20 ET31000.77
12:25 ET2000.77
12:27 ET105340.7401
12:30 ET371350.72
12:34 ET20000.7359
12:36 ET57000.75
12:38 ET52000.7878
12:48 ET13260.77
01:12 ET20000.770089
01:21 ET5000.78
01:37 ET1000.77
02:09 ET12500.77
02:15 ET1000.77
02:26 ET10000.774999
02:44 ET1000.7701
02:45 ET16000.775
02:58 ET16000.7702
03:27 ET1560.770501
03:30 ET1000.7704
03:36 ET7000.7703
03:54 ET11500.7799
03:56 ET1000.7771
03:57 ET1000.78
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTLPH
Talphera Inc
13.4M
-1.2x
---
United StatesTXMD
TherapeuticsMD Inc
18.5M
-3.8x
---
United StatesBQST
BioQuest Corp
6.9M
-12.4x
---
United StatesALID
Allied Corp
5.3M
-0.7x
---
United StatesSYBE
SYBLEU Inc
5.5M
-1.9x
---
United StatesSNBH
Sentient Brands Holdings Inc
3.7M
-3.5x
---
As of 2024-10-04

Company Information

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is its nafamostat formulation for direct intravenous (IV) infusion being explored as an investigational product for the antiviral treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. Its pre-filled syringe product candidates include Fedsyra and Phenylephrine.

Contact Information

Headquarters
1850 Gateway Drive, Suite 175SAN MATEO, CA, United States 94404
Phone
650-216-3500
Fax
302-636-5454

Executives

Independent Chairman of the Board
Adrian Adams
Chief Executive Officer, Director
Vincent Angotti
Chief Financial Officer
Raffi Asadorian
Chief Development Officer, Chief Medical Officer
Shakil Aslam
Chief Engineering Officer
Badri Dasu

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$13.4M
Revenue (TTM)
$398.0K
Shares Outstanding
17.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.33
EPS
$-0.64
Book Value
$0.83
P/E Ratio
-1.2x
Price/Sales (TTM)
33.7
Price/Cash Flow (TTM)
---
Operating Margin
-3,731.91%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.